Berlin named to new leadership post at Vanderbilt-Ingram Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jordan Berlin was named associate director of Clinical Investigation Strategy and Shared Resources at the Vanderbilt-Ingram Cancer Center.

In his new role, he will chair the Resource Allocation Committee and continue as chair of the Clinical Trials Shared Resource Steering Committee.

Berlin is an Ingram Professor of Cancer Research, and co-leader of the Gastrointestinal Cancer Research Program and director of the phase I Clinical Trials Program at VICC.

In his new role, Berlin will work closely with Vicki Keedy, medical director of the CTSR, Marta Crispens, chair of the Scientific Review Committee, Ingrid Mayer, chair of the Data and Safety Monitoring Committee, and the operational leaders of the CTSR to optimize operations and facilitate clinical trial services for the VICC membership.

Berlin joined the faculty at Vanderbilt in 1999. He specializes in treating GI cancers.

At VICC, Berlin is the principal investigator of Project 2 and co-director of the Administrative Core for the GI Specialized Program of Research Excellence, a prestigious research grant program funded by the National Cancer Institute.

He also is principal investigator of the Vanderbilt Lead Academic Participating Site Grant with the National Clinical Trials Network and of the UM1 to conduct early-phase trials with the Early Therapeutics Clinical Trials Network.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login